Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study-Reference-Cited by-同舟云学术

Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study

Published:2024-01-24 Issue:8 Volume:113 Page:1219-1231
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Wu Zhaogui^ORCID,Chen Shuohua,Tao Xixi,Liu Hangkuan,Sun Pengfei,Richards Arthur Mark,Tan Huay Cheem,Yu Ying,Yang Qing,Wu Shouling,Zhou Xin

Funder

National Natural Science Foundation of China

Tianjin Key Medical Discipline (Specialty) Construction Project

Natural Science Foundation of Tianjin Municipal Science and Technology Commission

First Clinical Medical School, Lanzhou University

First-Class Project of Tianjin Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00392-024-02381-x.pdf

Reference47 articles.

1. Magliano DJ, Boyko EJ, committee IDFDAtes (2021) IDF Diabetes Atlas. In: Idf diabetes atlas. International Diabetes Federation © International Diabetes Federation, Brussels

2. Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, Zhang X, Li C, Huang Z, Sun X et al (2021) Prevalence and treatment of diabetes in China, 2013–2018. JAMA 326:2498–2506. https://doi.org/10.1001/jama.2021.22208

3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e1046–e1081. https://doi.org/10.1161/cir.0000000000000624

4. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188. https://doi.org/10.1093/eurheartj/ehz455

5. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 55:1209–1216. https://doi.org/10.1016/j.jacc.2009.10.053